Status:
RECRUITING
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
Lead Sponsor:
Jiangsu vcare pharmaceutical technology co., LTD
Conditions:
Non-segmental Vitiligo
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study
Eligibility Criteria
Inclusion
- The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol.
- The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.
Exclusion
- Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.
- All hair in the vitiligo area on the face is white.
- Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs.
- Subjects who have previously received depigmentation treatment.
- Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.
Key Trial Info
Start Date :
October 31 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2027
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT07172347
Start Date
October 31 2025
End Date
August 30 2027
Last Update
January 2 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Peking University People's Hospital
Beijing, Beijng, China